Behavioural studies with a newly developed neuroprotective KYNA-amide

Area of Science:

• Neuroscience
• Pharmacology
• Medicinal Chemistry

Background:

• Endogenous kynurenic acid (KYNA) has demonstrated neuroprotective properties but poor blood-brain barrier (BBB) penetration.
• KYNA's antagonist activity at the glycine co-agonist site has been a target for neuroprotection.
• Developing KYNA analogs that can cross the BBB is crucial for therapeutic applications.

Purpose of the Study:

• To evaluate the neuroprotective potential and cognitive effects of a novel KYNA-amide analog.
• To assess the analog's ability to cross the BBB and its impact on animal behavior.
• To determine if the KYNA analog offers therapeutic benefits without adverse cognitive side-effects.

Main Methods:

• Administration of the novel KYNA-amide analog via intraperitoneal injection.
• Assessment of locomotor activity using the open field (OF) paradigm in mice.
• Evaluation of spatial learning and memory using the Morris water maze (MWM) and radial arm maze (RAM) paradigms in rats and mice, respectively.

Main Results:

• The novel KYNA-amide analog demonstrated neuroprotective effects in animal models.
• A specific dose was identified that provides neuroprotection without impairing cognitive functions such as working memory and spatial learning.
• Behavioral assessments in MWM and RAM indicated no adverse effects on learning and memory at neuroprotective doses.

Conclusions:

• The developed KYNA-amide analog successfully crosses the BBB and exhibits significant neuroprotective capabilities.
• This analog represents a promising therapeutic candidate for neurological disorders, offering neuroprotection without cognitive impairment.
• The findings highlight the potential of BBB-penetrant KYNA derivatives in developing safer and more effective neuroprotective agents.